research published 2019-04-01 · by Chalmers LJ, Condren M, Hopwood J, Sabet S, Saley T

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2019 Mar-Apr

PubMed #31019402

Abstract

Type 1 diabetes mellitus has witnessed significant progress in its management over the past several decades. This review highlights technologic advancements in type 1 diabetes management. Continuous glucose monitoring systems are now available at various functionality and cost levels, addressing diverse patient needs, including a recently US Food and Drug Administration (FDA)-approved implantable continuous glucose monitoring system (CGMS). Another dimension to these state-of-the-art technologies is CGMS and insulin pump integration. These integrations have allowed for CGMS-based adjustments to basal insulin delivery rates and suspension of insulin delivery when a low blood glucose event is predicted. This review also includes a brief discussion of upcoming technologies such as patch-based CGMS and insulin-glucagon dual-hormonal delivery.

Neurotransmitters

None linked yet.

Related

Community votes: 0

Ratings (0): Breadth — · Depth — · Enjoyment — · Usefulness —

Community

Log in to rate and share your notes.

No contributions yet.